The c-abl gene codes for a protein-tyrosine kinase and is expressed in most examined murine cell types as two distinct mRNA species of 5.5 kilobases (kb) and 6.5 kb. In mouse testis, an additional species of 4.0 kb is expressed in very high levels. To study the interrelationship between various c-abl transcripts and to compare their sequence with the v-abl transcript, we prepared c-abl-specific cDNA clones from mouse testis and determined the complete nucleotide sequence of the 4.0-kb cDNA that appears to be the reverse transcript of the testis-specific mRNA. In addition, we have determined the 3' sequence of an additional clone derived from the larger mRNA species that is expressed in somatic as well as germ-line cells. These cDNA sequences have been compared with the v-abl sequences to understand the mechanism of activation of this oncogene. The results demonstrate that (i) testis-specific c-abl mRNAs arise as a result of 3' truncation, and (it) the v-abl gene has arisen from its cellular homologue as a result of an extensive deletional/mutational process.
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Abelson murine leukemia virus (Ab-MuLV) arose by recombination of nondefective helper virus [Moloney murine leukemia virus (Mo-MuLV)] sequences with cellular sequences present within the normal mouse genome (1) (2) (3) . The latter sequences, termed abl, code for the transforming properties of this virus. In addition to its activation by viral transduction, the ABL gene is also activated in human chronic myelogenous leukemia, which is characterized by a reciprocal translocation between chromosomes 9 and 22 (4) (5) (6) . This translocation results in the synthesis of an altered protein where the amino-terminal sequences of ABL are replaced by BCR gene sequences (4) (5) (6) (7) .
A comparative study of retroviral oncogenes and their cellular homologues has given important information regarding the structural changes that protooncogenes often undergo to acquire transforming potential. Toward this goal, we had earlier reported cloning and sequence analysis of the AbMuLV proviral genome (2, 8) . To compare the structure of this viral oncogene with its normal cellular counterpart, we have undertaken the cDNA cloning and sequencing of the c-abl-specific mRNAs. The c-abl gene appears to be expressed in most examined murine cell types as two distinct mRNA species of 5.5 kilobases (kb) and 6.5 kb (9) . In mouse testis, an additional species of4.0 kb is expressed in very high levels along with the 5.5-and 6.5-kb species (10) (11) (12) . To study the interrelationships between the various c-abl transcripts and to compare their sequence with the v-abl transcript, we prepared c-abl-specific cDNA clones from mouse testis and determined the complete nucleotide sequence of the 4.0-kb cDNA § that appears to be the reverse transcript of testisspecific mRNA. In addition we have determined the 3' sequence of an additional cDNA clone that is derived from the larger mRNA species (5.5-to 6.5-kb size) § that are present in somatic as well as germ-line cells. These cDNA sequences have been compared with the v-abl sequences to understand the mechanisms involved in the activation of this oncogene.
MATERIALS AND METHODS
RNA Preparation and cDNA Library Construction. RNA was prepared from adult mouse testes or from mouse thymuses by the method of Auffray and Rougeon (13) . Poly(A)-containing RNA was selected by two cycles of purification on oligo(dT)-cellulose. Electrophoretic analysis of the RNA was carried out as described (14) . The cDNA library was constructed as described previously (15) . Fifty nanograms of cDNA was ligated to 1 ug of X GT1O arms to obtain a phage library of 100,000 recombinants. Screening of the library was as described by Benton and Davis (16) .
DNA Sequence Analysis. DNA sequence analysis was done by the method of Maxam and Gilbert (17) .
RESULTS
Cloning of the Testis-Specific c-qIbe cDNA. The source of the mRNA used for the construction of the cDNA library was adult mouse testis (10) (11) (12) . RNA blot analysis showed this preparation to contain three predominant species of 4.0-, 5.5-and 6.5-kb abl-specific mRNAs, whereas the RNA isolated from the thymus lacked the 4.0-kb species (Fig. 1) . The cDNA preparation from testis was size selected on lowmelting agarose gels, and only the DNA fragments that were longer than 2.5-kilobase pairs (kbp) were used for ligation to X GT10 arms. Screening a library of 100,000 recombinants yielded 14 positive clones. To test whether 3' heterogeneity could account for the difference in size between the 4.0-kb and larger mRNAs, we analyzed the cDNA clones for the presence of HindIll and BamHI sites, which are known to be present towards the 3' end of the v-abl genome. These results indicated that 12 ofthese positive clones did not contain these two restriction sites, whereas the other two clones did contain them. Fig. 2 and thymus mRNAs. RNA was isolated from pooled testes or thymuses as described (12) and analyzed on 1% agarose gels (13) . Lanes: A, mouse thymus poly(A)+ RNA; B, mouse testis total RNA; C, mouse testis poly(A)+ RNA. Hybridization was done using a v-ablspecific probe. Numbers at left are in kb.
within the poly(A) tail of their cognate mRNAs. The predominance of clones that lacked these two restriction sites indicated that such clones might be derived from the testisspecific 4.0-kb species, whereas the other two might derive from the larger mRNAs because 4.0-kb mRNA is present at least five to ten times in larger abundance compared with the 5.5-and 6.5-kb species (see Fig. 1 ). Analysis of the clone sizes on agarose gels revealed that all the clones lacking the BamHI and HindIII sites were between 3.8 and 4.0 kb in size, further suggesting that these clones derive from the 4.0-kb RNA species and represent nearly full-length cDNA clones.
Nucleotide Sequence of Testis-Specific c-abl cDNA Clones. The primary nucleotide sequence of a 4.0-kb cDNA clone was determined according to the method of Maxam and Gilbert (17) and is shown in Fig. 3 Computer analysis of the predicted protein sequence detecfed no extended hydrophobic regions that could serve as transmembrane signals. The tyrosine phosphorylating kinase region (19) spans amino acids 235-486 and includes an ATP binding site (20) composed of the conserved 9-amino acid peptide at position 248-256 and a lysine at position 271. The tyrosine residue that is phosphorylated in vitro appears at position 393 in the sequence presented. Comparison of the predicted amino acid sequence of the normal mouse protein with the analogous human sequence (21) shows that the two proteins share an overall homology of 90%.
Four hundred and sixty base pairs downstream to the translation-termination signal, a stretch of 20 adenines were seen that appear to constitute the poly(A) tail of its cognate mRNA. This poly(A) stretch appeared at an unusual locus in this sequence because no known polyadenylylation signals
(such as the AATAAA sequence known to occur in most eukaryotic genomes) were seen upstream to this sequence. The sequence that came closest to the consensus sequence was TACAAA present at position 3867-3873. To determine whether the short stretch of poly(A) sequence present at the 3' end of the 4.0-kb cDNA clones were due to poor polyadenylylation of this mRNA, we determined the 3' sequence of four of the 4.0-kb cDNA clones and found that all of them had a poly(A) tail that was 12-20 bases in size,
suggesting that the short adenine stretch is characteristic of the 4.0-kb c-abl mRNA. Nucleotide Sequence of the 3' End of the Larger c-abl mRNAs. To determine whether the 3' ends of the other testis-specific mRNAs have unique sequences, we analyzed the nucleotide sequence of the 3' end of one cDNA clone that contained the BamHI and HindIII sites. Sequence analysis of this clone (Fig. 4 ) indicated that the cDNA has an identical translational terminator sequence to that seen in the 4.0-kb mRNA and the v-abl sequence. However, a second open reading frame that could code for a protein of 18 kDa was seen in this sequence. We had previously noticed this open reading frame in the v-abl genome (2) . Because the sequence of the c-abl gene was unknown at that time, it had been unclear whether the two open reading frames seen in the v-abl genome originated from a single larger open reading frame as a result of point mutations and/or deletions. The present analysis demonstrates that this is not the case and that the larger c-abl mRNAs contain the second open reading frame. A large part of this sequence is deleted in the 4.0-kb testis-specific mRNA because of premature termination of transcription. These results also formally demonstrate that the larger mRNAs present in the testis have the same 3' end as is seen with c-abl mRNAs of somatic cells (1) .
Comparison of v-abl and c-abl Sequences and Implications for abl Oncogene Activation. To understand the molecular mechanisms involved in the oncogenic activation of the abl gene, we compared the sequence of the viral genome with the cDNA sequences reported here. Two prototypes of Abelson virus, designated P120 and P160, are known to occur in nature, and both these virus strains have been cloned and their nucleotide sequence has been determined (2, 3, 8, 22) . A comparison of the DNA sequence of the two strains revealed that strain P120 has probably arisen from P160 by an in-frame deletion of 789 bp from the middle of the coding sequences. A comparison of the c-abl sequence presented in Figs. 3 and 4 with the v-abl sequence of P120 strain (Fig. 5 ) reveals that the viral gene has replaced 114 codons from the 5' end of the c-abl gene with 240 codons derived from the gag gene of Mo-MuLV. Furthermore, the viral gene is deleted for an additional stretch of 263 codons from the middle of the coding sequences. In addition to the coding sequences, a stretch of 765 bp of noncoding sequences have been deleted from the 3' end. Further, in addition to these deletions, one point mutation was observed at position 2545 of the c-abl sequence presented in Fig. 2 . This results in the substitution A comparison of the cDNA sequences with the P160 strain of a glutamic acid residue with lysine in the v-abl-encoded ofAb-MuLV (22) 4 . Nucleotide sequence of the 3' end of a c-abl cDNA clone derived from larger (5.5-kb or 6.5-kb) c-abl mRNAs. The sequence derived from the 3' end of A21 is shown. The position where the testis-specific c-abl cDNA sequences end is shown by an arrow. The position of HindIII and BamHI sites that are absent in testis-specific c-abl cDNA are shown. The translated sequence of the open reading frame that could code for the putative 18-kDa protein is also shown. For comparative purposes, the same numbering was used at the start of the sequence as that in the clone A16 described in Fig. 3 .
be missing in the viral sequence, whereas an additional guanine has been inserted into the viral genome at the position 2050 of the corresponding cDNA sequence (see Fig.  3 ). These two frame-shift mutations render a stretch of69 bp, coding for 23 internal amino acids, out-of-frame, changing entirely the amino acid sequence of the viral protein in this region. Thus, in the P120 strain of Ab-MuLV, this entire region has been deleted, whereas in the P160 strain, the sequence of the viral genome is altered in the corresponding region as a result of two frame-shift mutations. These results, taken together, indicate that the deletion of amino-terminal sequence, as well as the alteration of the middle region of the c-abl gene, might play a crucial role in its oncogenic activation.
DISCUSSION
Earlier studies had indicated that the c-abl gene of mouse is expressed in virtually all tissues examined, usually as two distinct mRNA species of 5.5 kb and 6.5 kb (9) . Expression of the c-abl gene appears to be maximal in testis, where both the 5.5-kb and 6.5-kb species are made, along with another species of4.0 kb that is expressed at 5-to 10-fold higher levels compared with the two other species (10-12, Fig. 1 ). The (23), who examined the 5' sequence of cDNA clones derived from the 5.5-kb and 6.5-kb mRNAs. These studies indicated that this variation arises as a result of differential splicing of 5' exons, which results in the generation of mRNAs that are divergent at the 5' end but contain a common sequence at the 3' end. Because these cDNAs were prepared from a B-lymphoid cell line, the molecular mechanisms involved in the generation of the 4.0-kb abl-specific mRNA could not be studied. In this communication, we have isolated the cDNA clones for the cognate 4.0-kb mRNA and determined its complete nucleotide sequence. The cDNA clones isolated by us seem to represent near full-length clones because they closely correspond to the size of mRNA and virtually all the clones derived from the testis-specific mRNA terminate within 20 bp of each other at the 5' end. Our sequence analysis of the testisspecific cDNA clones indicates that the 4.0-kb c-abl RNA is produced in the testis as a result of premature termination of transcription. Polyadenylylation of this RNA was found to occur at an unusual place where no consensus polyadenylylation signal was seen. The 5' sequence of this cDNA clone corresponds to the sequence of type 1 c-abl cDNA described by Ben-Neriah et al. (23) . Thus, it appears that the variation in the 4.0-kb mRNA is primarily at the 3' end. The mechanism by which this short mRNA is produced is at present unknown. It is likely that testis cells contain special enzymes that have different sequence specificity for transcription termination and polyadenylylation compared with their somatic cell counterparts. This agrees with the observation that several mRNA species produced in testis have smaller sizes compared with their somatic cell counterparts (24) . For mouse c-abl-specific mRNAs, the truncation results in the deletion of 3' sequences that contain an open reading frame that could code for an 18-kDa protein. In addition, a stretch of 1.0 kb of noncoding sequences that are otherwise present in the two larger mRNAs is deleted in the 4.0-kb mRNA. The 4.0-kb mRNA could be generated specifically to avoid the synthesis of 18-kDa protein in large quantities in testis. However, there is no experimental evidence indicating that this short reading frame codes for a polypeptide. Alternatively, the 3' sequences might code for control signals that determine the message stability and translational efficiency of the mRNAs (25) (26) (27) . The deletion of the 3' sequences in such an instance would be expected to result in the decreased turnover and increased translatability of the mRNA, consistent with the presence of high levels of 4.0-kb mRNA in testis cells compared with 5.5-kb and 6.5-kb species. The transcriptional promoter sequence that is used for the synthesis of the 4.0-kb RNA is at present unknown. Though our testisspecific c-abl cDNA clones have an identical 5' end as that of type 1 cDNA of Ben-Neriah (which is derived from either 5.5-kb or 6.5-kb mRNA), the 5.5-kb mRNA would be predicted to have at least 500 bp of additional sequences at its 5' end to account for the size difference. Should this prediction prove accurate, the 4.0-kb mRNA might be produced from a promoter distinct from those used for the synthesis of the 5.5-kb and 6.5-kb mRNAs. This situation is consistent with the finding of Shtivelman et al. (21) , who showed that the 6.0-kb and 7.0-kb c-abl mRNAs in the human cells use different promoters for their transcription.
The availability of full-length cDNA clones for the c-abl mRNA has allowed us to determine its complete nucleotide sequence and compare it with v-abl sequence (see Fig. 5 ). Both the P120 and P160 strains have deleted 114 codons at the 5' end and have replaced these sequences with 240 codons derived from the gag gene of Mo-MuLV. In addition, the P120 strain has 263 codons deleted from the middle of the coding region. The P160 strain, while retaining these sequences, has suffered two frame-shift mutations in this region that render a stretch of 69 bp (codon for 23 internal amino acids) out of reading frame, changing the amino acid sequence of this stretch of coding sequences. Recently a feline sarcoma virus that also transduced the abl gene has been isolated, and its sequence has been determined (28) . During the transduction process, this virus has eliminated 51 codons from the 5' end and all the sequences downstream to the 490th codon of the c-abl sequences. Thus, this virus also has been deleted in both 5' and 3' sequences close to the region where the Ab-MuLV (P120) sequences have undergone deletion. These results lend further support to the argument that the amino-and carboxyl-terminal deletions play an important role in the oncogenic activation of c-abl. In addition to the frame-shift mutations/deletions, the v-abl gene has suffered one point mutation at position 2545 (of c-abl sequence shown in Fig. 3) , which results in the substitution of a glutamic acid residue with lysine in the v-abl gene product (2) .
In the human system, Philadelphia chromosome-positive chronic myelogenous leukemia cells have been shown to undergo translocations in the ABL locus that result in the formation of BCR/ABL fusion product (4-7, 18, 21, 29) . In this case, 26 codons derived from the 5' end of the ABL gene are replaced with 927 codons from the BCR gene. However, in this system no mutations or deletions have been observed near the 3' end. Thus amino-terminal deletions alone seem to be involved in the activation of this gene. Recent reports (29) indicate that recombinant retroviruses coding for BCR/ABL product do not transform NIH 3T3 cells or B lymphocytes in vitro, suggesting that BCR/ABL gene product is less potent in its oncogenic activity than the Ab-MuLV-encoded GAG/ABL gene product. It is possible that the 3' deletions and mutations play an important role in potentiating the oncogenic activity of this transforming gene. The availability of full-length c-abl cDNA clones should facilitate the construction of recombinants between v-abl and c-abl sequences, as well as v-abl and bcr/abl sequences that should resolve the role of 5' and 3' deletions and mutations in the activation of the c-abl gene.
